Skip to main content
    S

    Silexion Therapeutics Corp (SLXN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.76
    -0.22 (-11.11%)

    Market Cap: $1.29M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Silexion Therapeutics Corp (SLXN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Silexion Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$11.91M, operating cash flow was -$10.82M and free cash flow was -$10.83M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$2.53M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $11.63M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021N/AN/AN/AN/AN/A
    Dec 2020N/AN/AN/AN/AN/A
    Dec 2012N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2012 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2012
    Research and development$7.14M$5.82M$3.71M$3.23M$0$0$0
    Operating income-$11.63M-$12.57M-$4.68M-$3.86M-$943.93K-$195.86KN/A
    Net income-$11.91M-$16.52M-$5.11M-$3.21M-$755.22K-$195.86KN/A
    EBITDAN/AN/AN/A-$3.32M-$755.00K-$195.86KN/A
    Fiscal years ended Dec 2012 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$55.00K$30.00K$0$0$0$0$0$0$0
    Gross profit$0$0$0$55.00K$30.00K$0$0N/A$0$0$0N/A
    Operating income-$2.68M-$3.68M-$2.75M-$4.32M-$3.29M-$2.28M-$1.65M-$1.90M-$8.04M-$1.39M-$1.25M-$1.73M
    Net income-$2.53M-$3.55M-$2.73M-$4.41M-$3.26M-$2.50M-$1.74M-$1.75M-$11.86M-$1.49M-$1.42M-$1.73M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $1.75M by $4.24M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2013Dec 2012
    Total assets$7.21M$2.86M$5.26M$9.33M$115.41M$129.40KN/AN/A
    Current assets$6.64M$2.25M$4.98M$8.84M$407.80K$51.70K$928.00K$1.79M
    Cash and equivalents$5.99M$1.19M$4.59M$8.26M$38.94K$51.70KN/AN/A
    Total liabilities$4.61M$6.85M$2.25M$16.41M$508.92K$299.39KN/AN/A
    Short-term debt$182.00K$1.16M$112.00K$115.00KN/AN/AN/AN/A
    Long-term debt$1.57M$2.96MN/AN/AN/AN/AN/AN/A
    Shareholder equity$2.60M-$3.99M-$15.48M-$10.66M$114.91M-$169.99KN/AN/A
    Fiscal years ended Dec 2012 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$6.83M$4.25M$4.60M$7.21M$11.61M$5.80M$8.31M$2.86M$3.09M$2.52M$3.58M$5.26M
    Total liabilities$3.86M$4.20M$4.31M$4.61M$4.64M$5.68M$5.72M$6.85M$7.67M$2.37M$17.03M$17.31M
    Cash and equivalents$4.76M$2.23M$2.41M$5.99M$9.24M$3.47M$6.15M$1.19M$1.97M$1.70M$2.78M$4.59M
    Shareholder equity$2.97M$44.00K$291.00K$2.60M$6.98M$120.00K$2.59M-$3.99M-$4.58M-$18.26M-$16.82M-$15.48M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$10.82M-$8.40M-$4.53M-$3.33M-$1.41M-$75.00K
    Capital expenditures$9.00K$22.00K$12.00K$40.00K$4$0
    Free cash flow-$10.83M-$8.42M-$4.54M-$3.38M-$1.41M-$75.00K
    Share repurchases$740.00K$0N/AN/AN/AN/A
    Investing cash flow-$14.00K-$22.00K$573.00K-$524.00KN/AN/A
    Financing cash flow$15.64M$5.10M$522.00K$2.75M$116.40M$126.70K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.11M-$2.92M-$3.65M-$3.02M-$2.84M-$2.51M-$2.45M-$2.93M-$2.65M-$1.06M-$1.75M-$1.26M
    Capital expenditures$42.00KN/A$0$2.00K$0$1.00K$6.00K$0$16.00K$0$6.00K$4.00K
    Free cash flow-$2.15MN/A-$3.65M-$3.02M-$2.84M-$2.51M-$2.46M-$2.93M-$2.67M-$1.06M-$1.76M-$1.26M
    Last 12 quarters

    Frequently Asked Questions About SLXN

    What is Silexion Therapeutics' annual revenue?

    Silexion Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Silexion Therapeutics profitable?

    No. Silexion Therapeutics reported net income of -$11.91M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does SLXN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.82M minus capital expenditures of $9.00K produced free cash flow of -$10.83M.

    How much debt does Silexion Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $1.57M, short-term debt of $182.00K and cash and equivalents of $5.99M.